Inducible nitric oxide synthase (iNOS) generates nitric oxide (NO) in myeloid cells that acts as a defense mechanism to suppress invading microorganisms or neoplastic cells. In tumor-bearing mice, elevated iNOS expression is a hallmark of myeloid-derived suppressor cells (MDSC). MDSCs use NO to nitrate both the T-cell receptor and STAT1, thus inhibiting T-cell activation and the antitumor immune response. The molecular mechanisms underlying iNOS expression and regulation in tumor-induced MDSCs are unknown. We report here that deficiency in IRF8 results in diminished iNOS expression in both mature CD11b+Gr1− and immature CD11b+Gr1+ myeloid cells in vivo. Strikingly, although IRF8 was silenced in tumor-induced MDSCs, iNOS expression was significantly elevated in tumor-induced MDSCs, suggesting that the expression of iNOS is regulated by an IRF8-independent mechanism under pathologic conditions. Furthermore, tumor-induced MDSCs exhibited diminished STAT1 and NF-κB Rel protein levels, the essential inducers of iNOS in myeloid cells. Instead, tumor-induced MDSCs showed increased SETD1B expression as compared with their cellular equivalents in tumor-free mice. Chromatin immunoprecipitation revealed that H3K4me3, the target of SETD1B, was enriched at the nos2 promoter in tumor-induced MDSCs, and inhibition or silencing of SETD1B diminished iNOS expression in tumor-induced MDSCs. Our results show how tumor cells use the SETD1B–H3K4me3 epigenetic axis to bypass a normal role for IRF8 expression in activating iNOS expression in MDSCs when they are generated under pathologic conditions. Cancer Res; 77(11); 2834–43. ©2017 AACR.
Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of immature myeloid cells (IMC) that include progenitors and precursors of dendritic cells, macrophages, and granulocytes of various differentiation stages (1). Under physiologic conditions, IMCs undergo a steady-state myelopoiesis and differentiate into mature dendritic cells, macrophages, and granulocytes (2, 3). Various pathologic conditions, including cancer, can perturb myelopoiesis and interrupt IMC differentiation, resulting in accumulation of MDSCs (2, 4–9). In human cancer patients and mouse tumor models, massive accumulation of MDSCs is a hallmark of tumor progression (10–16). MDSCs are therefore key targets in cancer immunotherapy (1, 17–21).
In mice, MDSCs were originally defined as CD11b+Gr1+ myeloid cells to reflect their myeloid origin, immunosuppressive function, and systemic expansion in a cancer host (22). Recent discoveries have expanded the definition of CD11b+Gr1+ MDSCs into polymorphonuclear MDSCs (PMN-MDSC) and monocytic MDSCs (M-MDSC) based on their phenotypic and morphologic features (4). MDSCs use several mechanisms to suppress T-cell activation and function (23, 24). Although the specific roles of these pathways in the inhibitory activity of MDSC subpopulations remain unclear, both PMN-MDSCs and M-MDSCs inhibit T-cell activation and function through nitric oxide–related pathways. PMN-MDSCs produce peroxynitrite to nitrate the T-cell receptor to render T cells unresponsive to antigen stimulation (25). M-MDSCs express a high level of inducible nitric oxide synthase (iNOS) to mediate nitration of STAT1 to block IFNγ signaling pathway, a key component of the host T-cell cancer immune surveillance system (26). Therefore, iNOS is a key mediator of M-MDSC suppressive function.
Although the expression regulation of iNOS has been extensively studied in various types of cells, including myeloid cells in vitro (27–30), the molecular mechanism underlying iNOS expression regulation in tumor-induced MDSCs is essentially unknown. We report here that the histone methyltransferase SETD1B regulates trimethylation of histone H3 lysine 4 (H3K4Me3) at the nos2 promoter to activate iNOS expression in tumor-induced MDSCs.
Materials and Methods
Tumor cells, mouse models, and human specimen collection
The mouse mammary carcinoma cell line, 4T1 (BALB/c mouse origin), was obtained from ATCC in 2004, and was stored in liquid nitrogen in aliquots. ATCC has characterized this cell line by morphology, immunology, DNA fingerprint, and cytogenetics. The AT3 cell line was derived from C57BL/6 mice and was kindly provided by Dr. Scott Abrams (Roswell Park Cancer Institute, Buffalo, NY) and was characterized as described previously (31). All cell lines in the laboratory are tested approximately every 2 months for mycoplasma. 4T1 and AT3 cells used in this study are mycoplasma negative. Cells were used within 30 passages after thawing an aliquot of cells from liquid nitrogen. 4T1 cells were injected subcutaneously into the mammary glands of BALB/c mice (1 × 104 cells/mouse) to establish the orthotopic breast tumors. AT3 cells were injected subcutaneously into the mammary glands of C57BL/6 mice (2 × 105 cells/mouse) to establish the orthotopic breast tumors. IRF8 knockout (KO) mice were kindly provided by Dr. Keiko Ozato (NIH, Bethesda, MD) and maintained at the Augusta University animal facility. All mouse studies are performed according to protocols approved by Augusta University Institutional Animal Care and Use Committee. Peripheral blood specimens were collected from consented healthy donors at the Shepeard Community Blood Center and from deidentified colon cancer patients at the Georgia Cancer Center Clinic (Augusta, GA). All studies of human specimens were performed according to protocols approved by Augusta University Institutional Human Research Protection Committee.
Treatment of tumor-bearing mice with chaetocin
Tumor-bearing mice were treated daily with an intraperitoneal injection of either solvent (10% Cremophor, 5% ethanol, and 85% PBS) or chaetocin (Sigma-Aldrich) starting at day 9 and day 21, respectively, at a dose of 0.5 mg/kg body weight for 3 days, followed by treatment at a dose of 0.25 mg/kg body weight for 4 more days.
Purification of tumor-induced MDSCs
Spleens cells were mixed with CD11b MicroBeads and loaded to LS columns (Miltenyi Biotec). MDSCs were eluted according to the manufacturer's instructions. The purified cells were stained with either IgG or CD11b- and Gr1-specific mAbs (BioLegend) and analyzed by flow cytometry.
Flow cytometry analysis
Spleen, lymph nodes, thymus, and bone marrow were collected from mice. Cells were stained with fluorescent dye–conjugated antibodies that are specific for mouse [CD11b, Gr1, Ly6G, and Ly6C (BioLegend)]. Stained cells were analyzed by flow cytometry.
Spleens, bone marrow, and tumor cells were collected from wild-type (WT) and IRF8 KO C57BL/6 mice. Tumor tissues were digested with collagenase solution (collagenase 1 mg/mL, hyaluronidase 0.1 mg/mL, and DNase I 30 U/mL). The buffy coat was prepared from human blood, and red cells were lysed with red cell lysis buffer. Mouse cells were stained with CD11b- and Gr1-specific mAbs (BioLegend). Human cells were stained with HLA-DR-, CD11b-, and CD33-specific mAbs (BioLegend). Stained cells were sorted using a BD FACSAria II SORP or a Beckman Coulter MoFlo XDP cell sorter to isolate myeloid cell subsets.
In vitro T-cell activation and coculture with MDSCs
Bone marrow cells were collected from WT tumor-free mice and seeded at a density of 6 × 106 cells in a 10-cm dish. 4T1 condition media were diluted with fresh culture medium at a 1:2 ratio and added to the bone marrow cell culture. CD3+ T cells were purified from spleen cells using the MojoSort mouse CD3+ T Cell Isolation Kit (BioLegend) according to the manufacturer's instructions. For T-cell activation, a 96-well culture plate was coated with anti-mouse CD3 and anti-mouse CD28 mAbs at 37°C for 2 hours. The purified T cells were labeled with 0.25 μmol/L CFSE (Life Technologies) and then seeded in the coated plate at a density of 1.5 × 105 cells/well in RPMI medium plus 10% FBS. Tumor culture supernatant-induced MDSCs were then added to the culture at a 1:2 ratio. Cells were then analyzed 3 days later by flow cytometry for T-cell CFSE intensity.
Gene expression analysis
Cells were homogenized in TRIzol (Life Technologies) to isolate total RNA. cDNA was synthesized from total RNA and used to analyze gene expression levels using gene-specific primers (Supplementary Table S1) by semiquantitative PCR or qPCR in the StepOnePlus Real-Time PCR System (Applied Biosystems). β-Actin was used as an internal control in each of the qPCR reactions. The expression level of each gene was normalized to the internal β-actin in each reaction.
Western blotting analysis
Western blotting analysis was performed as described previously (32). Anti-STAT1 and anti-pSTAT1 antibodies were obtained from BD Biosciences. Anti-p100/52, anti-p65, anti-p50, anti-RelB, and anti-cRel antibodies were obtained from Santa Cruz Biotechnology. Anti-H3K4me3, anti-H3, and anti-p-p65 antibodies were obtained from Cell Signaling Technology. Anti-β-actin was obtained from Sigma-Aldrich.
Inhibition of SETD1B enzymatic activity by chaetocin in vitro
Chaetocin was tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 μmol/L at Reaction Biology. Reactions were carried out with recombinant histone H3.3 (5 μmol/L), recombinant SETD1B protein (5 μmol/L), and [3H]S-adenosyl-L-methionine (1 μmol/L) in reaction buffer (50 mmol/L Tris-HCI, pH 8.5, 50 mmol/L NaCl, 5 mmol/L MgCI2, 1 mmol/L DTT, 1 mmol/L PMSF, and 1% DMSO). Reaction mixtures were incubated for 60 minutes at 30°C and then spotted onto a Whatman cellulose filter paper and counted in a scintillation counter.
Bone marrow cells from WT, tumor-free mice were cultured in the presence of 4T1 conditioned media for 6 days and transiently transfected with either scramble or two different mouse SETD1B-specific siRNAs using Lipofectamine 2000 (Life Technologies) for 2 days. Cells were collected and analyzed by qPCR for SETD1B and iNOS mRNA levels. The scramble and SETD1B-specific siRNA sequences are listed in Supplementary Table S1.
Chromatin immunoprecipitation (ChIP) was performed using anti-H3K4me3 antibody and protein A agarose beads (Millipore) according to the manufacturer's instructions as described previously (33). The immunoprecipitated genomic DNA was amplified by semiquantitative PCR using four pairs of PCR primers (Supplementary Table S1) covering the region from −3000 to +1000 relative to the nos2 transcription initiation site at the nos2 promoter region. The PCR band intensities were quantified using NIH ImageJ. The ratio of band intensities of the H3K4me3-specific antibody-immunoprecipitated DNA over input DNA was used to represent the H3K4me3 levels at the specific promoter region. The ChIP experiment was repeated and analyzed by qPCR using the nos2 promoter DNA-specific primers as above.
Statistical analysis was performed by two-sided Student t test using GraphPad Prism program (GraphPad Software, Inc.). A P < 0.05 was taken as statistically significant.
IRF8 is an essential transcriptional activator of both mature and immature myeloid cells under physiologic conditions
Spleen, lymph nodes, thymus, and bone marrow cells were collected from tumor-free WT and IRF8 KO mice and analyzed for CD11b+ and Gr1+ cells. Flow cytometry analysis validated that CD11b+Gr1+ cells increased dramatically in the spleen in IRF8 KO mice as compared with WT mice (Fig. 1A; ref. 34). To determine the function of IRF8 in the regulation of iNOS expression in both mature and immature myeloid cells under physiologic conditions, we sorted CD11b+Gr1− and CD11b+Gr1+ myeloid cells from the spleens of both WT and IRF8 KO mice. Few CD11b−Gr1+ cells were present in IRF8 KO mice and were not sorted (Fig. 1B). Analysis of CD11b+Gr1− and CD11b+Gr1+ cells by qPCR revealed that iNOS expression is diminished in both CD11b+Gr1− and CD11b+Gr1+ myeloid cells in IRF8 KO mice as compared with WT mice (Fig. 1B). CD11b+Gr1− and CD11b+Gr1+ myeloid cells were also isolated from bone marrow cells of WT and IRF8 KO mice and analyzed for iNOS expression. iNOS expression level was lower to undetectable in both WT and IRF8 KO CD11b+Gr1− and CD11b+Gr1+ bone marrow cells (Fig. 1C). These observations indicate that IRF8 is an essential transcriptional activator of iNOS in both mature and immature myeloid cells in vivo.
Tumor-induced MDSCs exhibit silenced IRF8 but elevated iNOS expression
To induce MDSCs, 4T1 tumor cells were injected into the mammary glands of BALB/c mice to generate orthotopic breast cancer (35). Analysis of lymphoid organs of tumor-free and tumor-bearing mice validated that CD11b+Gr1+ MDSCs massively accumulate in the spleen, bone marrow, and blood of tumor-bearing mice (31, 36). IRF8 expression is significantly lower in MDSCs from tumor-bearing mice as compared with their equivalent in tumor-free mice (Fig. 2A). However, iNOS expression is significantly higher in MDSCs from tumor-bearing mice than their equivalent in tumor-free mice (Fig. 2B). These observations indicate that IRF8 expression is diminished, whereas iNOS expression is elevated in MDSCs from tumor-bearing mice. Therefore, iNOS expression is regulated by an IRF8-independent mechanism under pathologic conditions.
To compare iNOS expression level in tumor-bearing WT and IRF8 KO mice, AT3 cells were injected into WT and IRF8 KO mice. Tumor-infiltrating CD11b+Gr1− and CD11b+Gr1+ cells were isolated and analyzed for iNOS expression level. No significant differences were observed in iNOS expression in both subsets of tumor-infiltrating myeloid cells between tumor-bearing WT and IRF8 KO mice (Fig. 2C). These observations further indicate that IRF8 plays no significant role in the regulation of iNOS expression in tumor-induced MDSCs in tumor-bearing mice in vivo.
iNOS expression and the IFNγ and NF-κB signaling pathways
In myeloid cells, iNOS expression is upregulated by IFNγ and NF-κB under physiologic conditions (27–29). To determine whether the elevated iNOS expression in MDSCs is regulated by IFNγ and NF-κB, MDSCs from the spleens of tumor-bearing mice and their equivalent in tumor-free mice were analyzed by Western blotting. STAT1, the key mediator of the IFNγ signaling pathway, is actually downregulated in MDSCs of tumor-bearing mice as compared with their equivalent from tumor-free mice. No activated STAT1 (pSTAT1) protein was detected in MDSCs from tumor-bearing and their equivalent in tumor-free mice (Fig. 3A). NF-κB has five Rel subunits. The canonical NF-κB complex can be combinations of any of the four following Rel subunits: p65, p50, RelB, and cRel. Western blotting analysis showed that the protein levels of all four subunits are lower in MDSCs from tumor-bearing mice (Fig. 3A). Similarly, the p52 subunit of the alternative NF-κB is also undetectable in MDSCs from tumor-bearing mice (Fig. 3A).
Next, bone marrow cells were cultured in the presence of 4T1 conditioned media to induce MDSC differentiation. 4T1 conditioned media effectively induced CD11b+Gr1+ MDSC differentiation (Fig. 3B). These MDSCs exhibit potent inhibitory activity against T-cell activation and proliferation (Fig. 3C), indicating that these MDSCs phenotypically and functionally resemble tumor-induced MDSCs. These bone marrow–derived MDSCs were then analyzed for IFNγ and NF-κB signaling components. Western blotting analysis detected STAT1 and p65 proteins in these MDSCs. IFNγ treatment induced STAT1 phosphorylation and TNFα induced phosphorylation of p65 in these bone marrow–derived MDSCs (Fig. 3D). There is no significant difference in iNOS expression level in bone marrow–derived MDSCs between WT and IRF8 KO mice. IFNγ treatment significantly increased iNOS expression in these bone marrow–derived MDSCs from both WT and IRF8 KO mice; however, bone marrow–derived MDSCs from IRF8 KO mice exhibited significantly higher IFNγ-induced iNOS expression than the MDSCs from WT mice (Fig. 3E). These observations suggest that IRF8 functions as a repressor in IFNγ induction of iNOS expression in bone marrow–derived MDSCs ex vivo.
SETD1B is upregulated and H3K4me3 is increased in tumor-induced MDSCs
We then hypothesized that iNOS might be regulated by an epigenetic mechanism in MDSCs of tumor-bearing mice. H3K4me3 is often associated with active chromatin and gene activation (37). We then analyzed H3K4me3 levels in MDSCs from the spleen of tumor-bearing mice and their equivalent in tumor-free mice. Western blotting analysis revealed indeed that H3K4me3 is higher in MDSCs from tumor-bearing mice as compared with their equivalent in tumor-free mice (Fig. 4A). H3K4me3 is catalyzed by five histone methyltransferases (38, 39). Analysis of these five histone methyltransferases showed that the expression level of SETD1B is upregulated in MDSCs from tumor-bearing mice as compared with their equivalent in tumor-free mice (Fig. 4B and C).
SETD1B increases H3K4me3 level to upregulate iNOS expression in tumor-induced MDSCs
We then made use of a SETD1B inhibitor chaetocin. Chaetocin inhibits SETD1B at an IC50 of 0.238 μmol/L (Fig. 5A). Chaetocin treatment of tumor-bearing mice significantly suppresses tumor growth when the tumor sizes are approximately 98 to 139 mm3 at the time of the start of the treatment (Fig. 5B, left). Because MDSC accumulation is associated with tumor size (40), to minimize the effects of tumor size on MDSC accumulation and SETD1B expression, tumors were allowed to grow to approximately 1,004 to 1,058 mm3. Chaetocin treatment did not significantly decrease the tumor size of the tumor-bearing mice with this extensive tumor burden (Fig. 5B, right). Chaetocin treatment did not change the levels of general MDSCs (Supplementary Fig. S1A), the PMN-MDSCs, or the M-MDSCs (Supplementary Fig. S1B). MDSCs were then purified from spleens of control and chaetocin-treated mice. The purity of MDSCs is about 90% (Fig. 5C), and similar between the control and chaetocin-treated mice (Fig. 5D). Western blotting analysis showed that chaetocin treatment decreases H3K4me3 levels in MDSCs in tumor-bearing mice (Fig. 5E). qPCR analysis revealed that chaetocin treatment also diminished iNOS expression in MDSCs in tumor-bearing mice (Fig. 5F). Therefore, iNOS upregulation is at least in part regulated by SETD1B-catalyzed H3K4me3 in MDSCs in tumor-bearing mice.
SETD1B regulates iNOS expression in tumor-induced MDSCs
A complementary approach was then used to validate the above finding that SETD1B regulates iNOS expression in tumor-induced MDSCs. Bone marrow cells were cultured in the presence of 4T1 conditioned media to induce MDSC differentiation. SETD1B expression was then silenced by two SETD1B-specific siRNAs (Fig. 6A). Silencing SETD1B diminished iNOS expression in MDSCs (Fig. 6B). Taken together, these observations indicate that SETD1B regulates iNOS expression in tumor-induced MDSCs.
To determine whether SETD1B regulates iNOS expression in human MDSCs, we isolated HLA-DR−CD11b+CD33+ myeloid cells from peripheral blood specimens of healthy human donors and colon cancer patients (Supplementary Fig. S2A). The level of HLA-DR−CD11b+CD33+ MDSCs varies greatly, ranging from 18.2% to 49.7% among the five colon cancer patients. The equivalent population of cells in normal donors ranges from 1.32% to 2.67%, which is lower than all five colon cancer patients (Supplementary Fig. S2B). SETD1B level also varies greatly in MDSCs among colon cancer patients, but its expression level is higher in 3 of the 5 cancer patients as compared with the 3 normal donors (Supplementary Fig. S2C). There is no correlation between the percentage of MDSCs and SETD1B expression level (Supplementary Fig. S2B and S2C). iNOS is undetectable in the MDSCs under the conditions used here.
SETD1B increases H3K4me3 levels at the nos2 promoter region in tumor-induced MDSCs
The abovementioned observation that inhibition of SETD1B enzyme activity decreases H3K4me3 levels and iNOS expression level in tumor-induced MDSCs in vivo suggests that SETD1B might directly regulate H3K4me3 at the nos2 promoter to activate nos2 transcription. To test this hypothesis, we performed ChIP analysis of H3K4me3 levels at the nos2 promoter region. Four pairs of PCR primers were designed to cover the region of the nos2 promoter from −3000 to +1000 relative to nos2 transcription initiation site (Fig. 7A). Purified MDSCs from the spleens of the control and chaetocin-treated mice were used to prepare chromatin fragments, and H3K4me3-specific antibody was used to immunoprecipitate the chromatin fragments. PCR analysis with the immunoprecipitated genomic DNA with the four primer pairs revealed that H3K4me3 is enriched at the nos2 promoter region upstream of the transcription start site (Fig. 7B and C). Chaetocin treatment significantly decreased H3K4me3 level in the region immediately upstream of nos2 transcription initiation site (Fig. 7B and C). Taken together, our data determine that SETD1B expression is upregulated in MDSCs and SETD1B regulates H3K4me3 at the nos2 promoter region to activate nos2 transcription in MDSCs in tumor-bearing mice.
iNOS expression regulation varies depending on cell types and species (30, 41). In myeloid cells, particularly in macrophages, TNFα and LPS/TLR ligand-activated NF-κB is a major regulator of iNOS expression (27, 28, 42, 43). NF-κB, once activated by LPS or TNFα, can activate iNOS expression (28, 44). The p65 and p50 homodimers of the canonical NF-κB directly bind to the nos2 promoter region to activate nos2 transcription in myeloid cells (28). In addition to NF-κB, inflammatory cytokines, such as IFNγ, have also been shown to regulate iNOS expression (27, 45). It has been shown that IFNγ regulates iNOS expression in an IRF8-dependent mechanism. Overexpression of IRF8 dramatically increased IFNγ-induced iNOS activation in macrophages, and this activation was abolished in IRF8-deficient macrophages. Furthermore, transduction of IRF8-deficient macrophages with IRF8-expressing retrovirus rescued IFNγ-induced iNOS gene expression, whereas transduction of WT and IRF8-deficient macrophages with IRF8-expressing retrovirus in the absence of IFNγ activation did not induce iNOS expression (27). These observations indicate that (i) IRF8 mediates IFNγ induction of iNOS expression in macrophages in vitro; and (ii) constitutive IRF8 does not activate iNOS expression in macrophages in vitro.
In this study, we isolated both mature and immature primary myeloid cells from WT and IRF8 KO mice (34) and observed that IRF8 deficiency results in diminished iNOS expression in both mature and immature primary myeloid cells. It is unlikely that these myeloid cells are exposed to IFNγ as both WT and IRF8 KO mice are healthy mice without any treatment. Therefore, our observations suggest that constitutively expressed IRF8 functions as an iNOS transcription activator in myeloid cells in vivo. IRF8 is both constitutively expressed and IFNγ inducible in myeloid cells (27, 45). The observations that IRF8 does not regulate iNOS expression in the absence of IFNγ in macrophages in vitro (27) but regulates iNOS expression in myeloid cells in vivo suggest that IRF8 functions differently in in vitro–cultured myeloid cells than in primary myeloid cells in vivo.
IRF8 is known to be silenced in tumor-induced MDSCs from both human patients and tumor-bearing mice (31, 36). However, iNOS expression is elevated in MDSCs from tumor-bearing mice (26, 46). Thus, IRF8 expression is inversely correlated with iNOS expression in MDSCs of tumor-bearing mice, which is in contrast to IRF8 function in iNOS expression in myeloid cells in tumor-free mice under physiologic conditions. On the other hand, although no pSTAT1 and p-p65 proteins are detected in tumor-induced MDSCs in vivo, tumor condition medium-induced and bona marrow–derived MDSCs ex vivo respond to IFNγ and TNFα to activate STAT1 and NF-κB p65, suggesting that MDSCs are responsive to the IFNγ and NF-κB signaling pathways, but the IFNγ and NF-κB signaling pathways are not activated in MDSCs in the tumor-bearing mice in vivo. In contrast to what was observed in myeloid cells from tumor-free WT and IRF8 KO mice, tumor conditioned medium–induced MDSCs from WT and IRF8 KO mice exhibit no significant difference in iNOS expression. Furthermore, IFNγ induced significantly higher iNOS expression in bone marrow–derived MDSCs from IRF8 KO mice than from WT mice, which is in contrast to what was reported in the in vitro–cultured macrophages (27). Because IFNγ can also induce IRF8 expression in WT myeloid cells (27, 45), these observations suggest that IRF8 functions as an iNOS repressor in tumor-induced MDSCs, which might use IRF8 silencing as a mechanism to increase iNOS expression under pathologic conditions. IRF8 is an essential transcription factor for myeloid and T-cell lineage differentiation and maturation and can function as either a transcription activator or repressor depending on which cofactors it binds to under physiologic conditions (34, 43, 47–50). The contrasting functions of IRF8 in iNOS expression regulation and IFNγ induction of iNOS expression in myeloid cells and tumor-induced MDSCs might be controlled by different components of the IRF8 protein complexes in these cells, which require further studies.
We observed here that the expression level of SETD1B, a histone methyltransferase that catalyzes H3K4me3, is upregulated in tumor-induced MDSCs. Consistent with elevated SETD1B expression levels, H3K4me3 mark is enriched at the nos2 promoter region in tumor-induced MDSCs. Furthermore, inhibition of SETD1B decreased H3K4me3 level at the nos2 promoter region and diminished iNOS expression in MDSCs in tumor-bearing mice. Our data thus determine that the SETD1B–H3K4me3 epigenetic axis regulates iNOS expression in MDSCs in tumor-bearing mice, which represent a novel molecular mechanism underlying iNOS expression regulation in tumor-induced MDSCs. However, how SETD1B is upregulated in MDSCs in tumor-bearing mice also requires further study. Nevertheless, our data suggest that tumor-induced MDSCs might use the upregulation of the SETD1B–H3K4me3 pathway to activate iNOS expression and execute its immunosuppressive function. Thus, targeting SETD1B expression in MDSCs might represent an effective approach to inhibit MDSC function in immunosuppression and thus to improve the efficacy of cancer immunotherapy.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Conception and design: P.S. Redd, M.L. Ibrahim, A.V. Paschall, A. Nayak-Kapoor, K. Liu
Development of methodology: P.S. Redd, M.L. Ibrahim, J.D. Klement, A.V. Paschall, D. Yang
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): P.S. Redd, M.L. Ibrahim, J.D. Klement, S.K. Sharman, A.V. Paschall, D. Yang, A. Nayak-Kapoor
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): P.S. Redd, M.L. Ibrahim, K. Liu
Writing, review, and/or revision of the manuscript: P.S. Redd, M.L. Ibrahim, A.V. Paschall, A. Nayak-Kapoor, K. Liu
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): K. Liu
Study supervision: K. Liu
We thank Dr. Jeanene Pihkala at the Medical College of Georgia Flow Cytometry Core Facility and Dr. Ningchun Xu at Georgia Cancer Center Flow Cytometry Core Facility for assistance in cell sorting. We would also like to thank Dr. Wei Xiao for his assistance in flow cytometry. In addition, we thank Jennifer Parks and Susan Dewes for their assistance in obtaining blood specimen from consented healthy donors at the Shepeard Community Blood Center.
This work was supported by NIHCA133085 and NIHCA182518 (K. Liu), VA Merit Review Award I01BX001962 (K. Liu.), and NIAIDAI120487 (A.V. Paschall).
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.